In terms of effectiveness, Mounjaro (Tirzepatide) is the strongest of commonly prescribed weight loss medications, including Wegovy, Mysimba, Xenical, Alli, and Saxenda. Once-weekly use of Mounjaro can result in losing about 15% of body weight after 72 weeks. Although marked differences exist in the weight loss potential for these medications, they are prescribed according to the individual's unique needs.
Many pharmacological options, in addition to lifestyle modifications, are now available to help with weight loss. However, their effectiveness varies, as explained below.
Mounjaro has an active ingredient, “Tirzepatide,” which is usually prescribed for weight loss in adults with significant obesity. A clinical trial revealed that the mean percentage change in weight was 15% at week 72, with 5mg once-weekly doses. This considerable weight loss with Mounjaro makes it the strongest prescription medicine for obesity.
Wegovy contains an active ingredient, “Semaglutide,” the second strongest among common weight loss prescription medicines. According to a clinical study, the mean change in body weight from baseline to week 68 was 12.4%. Simply put, Wegovy 2.4mg can help lose 12.4kg (on average) in a 100 kg person after 68 weeks.
Since 2020, Saxenda (Liraglutide) has been a licensed treatment for weight management in the UK. Clinical studies have shown that obese people using Saxenda achieved the target goal of 8% at 56 weeks.
Mysimba is a combination of two active ingredients, Naltrexone and Bupropion, used for weight loss in obese adults. According to several clinical studies, Mysimba can reduce body weight by an average of 5-10%. However, it is considered less safe than other weight loss prescription medications due to its increased risk of adverse events.
Orlistat is an oral weight loss medication used for weight reduction in adults. Similar to Xenical, Alli is another oral weight loss pill containing low-dose Orlistat. Trials have revealed that the mean weight loss achieved per year with orlistat is usually 2-5 kg more than that achieved with placebo. (or no treatment). The average weight loss with Orlistat medications is around 5-10%.
Here’s a brief table to overview the differences in weight loss medications, mentioning their mechanism of action, weight loss potential, and routes of administration.
Medication | Active Ingredient | Mechanism of Action | Weight Loss Potential | Schedule | Route of Administration |
---|---|---|---|---|---|
Mounjaro | Tirzepatide | GLP-1 and GIP receptor agonist: It reduces appetite and slows down stomach emptying. | 15% of body weight | Once Weekly | Subcutaneous injection |
Wegovy | Semaglutide | GLP-1 receptor agonist: It promotes appetite control by reducing hunger. | 12.4% of body weight | Once Weekly | Subcutaneous injection |
Saxenda | Liraglutide | GLP-1 receptor agonist: It promotes appetite control by reducing hunger. | Around 8% of body weight | Once Daily | Subcutaneous injection |
Mysimba | Naltrexone and Bupropion | It acts on the brain pathways, reducing hunger and promoting appetite control. | 5-10 % of body weight | Twice a day | Oral tablet |
Xenical or Alli | Orlistat | It blocks fat-absorbing enzymes (lipases), decreasing the fat absorption from food into the body. | 5-10% of body weight | Recommended with fatty meals | Oral tablet |
Although these medications seem similar for weight management, it is essential to understand that they are usually prescribed according to the individual’s unique needs and prescription criteria. For example, NICE guidelines recommend using Saxenda (Liraglutide) for weight reduction only in people with a body mass index (BMI) of at least 35kg/m2, non-diabetic high blood sugar levels, and a cardiovascular risk factor like hypertension.
On the other hand, Orlistat can be used in people with a BMI of 30kg/m2 or a BMI of 28kg/m2 who have risk factors such as diabetes, hypertension, or increased cholesterol levels. Thus, it is not the strongest weight loss medication that should always be used, but the most suitable one.
Yes. These medications should be used as an adjunct to a reduced-calorie diet and exercise for optimal weight reduction rather than as a single-tier treatment.
Alli (which contains Orlistat in lower doses) can be purchased without a prescription (OTC) in the UK. However, as advised by the NHS, it should be used under the supervision of a pharmacist.
Sources
The New England Journal of Medicine 2022. Tirzepatide Once Weekly for the Treatment of Obesity
NICE guidelines 2023. Semaglutide for managing overweight and obesity
The British Journal of Diabetes 2021. Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology
British Journal of Clinical Pharmacology 2020. Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports
National Library of Medicine 2017. Obesity drug endorsed by NICE
NHS 2023. Treatment-Obesity
Additional Resources
Buy Wegovy Online For Weight Loss
At what dose does Wegovy start working
© 2013 - 2024 Al Muhsineen Limited. All Rights Reserved. Registered Pharmacy: 34 Halliwell Road, Bolton BL1 8RL. Registered Office: 254 First Floor, Shearbrow, Blackburn, England, BB1 8DS